Contents 5 sections
Accelerating Clinical Evidence Synthesis with AI While Staying Regulatory-Compliant
Clinical evidence synthesis is slow, expensive, and high-risk when done manually. Every day lost delays submissions, patient access, and competitive positioning. Yet moving faster without breaching HIPAA, GxP, or 21 CFR Part 11 is non-negotiable. AI can shorten timelines from months to weeks while keeping your compliance posture intact.
Why This Matters in Regulated Industries
Pharma and life sciences operate under strict frameworks. HIPAA governs patient data privacy. GxP ensures good manufacturing and clinical practices. 21 CFR Part 11 sets rules for electronic records and signatures. Any evidence synthesis process that touches patient records, trial data, or manufacturing documentation must meet these standards.
Traditional synthesis involves manual review of hundreds of documents, trial reports, and regulatory filings. This is prone to delays and human error. In regulated industries, errors trigger audits, fines, and reputational damage. AI can automate retrieval, classification, and summarization of evidence while embedding compliance checks into every step.
When deployed in production, AI systems can operate within your governance controls. They can log every action, enforce access controls, and maintain audit trails required by regulators.
A Practical Plan for This Quarter
To accelerate synthesis without breaking compliance, follow a structured deployment plan.
- Scope and Agreement We scope one workflow with you, sign an agreement on the deliverables and the acceptance criteria you signed off on.
- Build Deploy an Pharma & Life Sciences AI solution in your environment. Configure retrieval-augmented generation (RAG) to pull evidence from validated repositories. Add compliance and risk agent modules to enforce HIPAA and GxP constraints.
Key Compliance Checks
- Verify all source systems are validated under 21 CFR Part 11.
- Ensure AI outputs are traceable to original documents.
- Apply role-based access to protect patient-identifiable information under HIPAA.
- Maintain immutable audit logs for regulatory inspections.
What Good Looks Like
- Evidence review cycles shortened.
- Zero compliance violations in regulatory audits.
- Cost avoidance from reduced manual review hours.
- Consistent audit trails accessible within minutes.
- Full production deployment.
Good means the system is live, integrated, and delivering measurable outcomes. Pilots that never ship do not qualify.
Next Steps
If you want to move from manual synthesis to compliant AI, start with a focused build. Tell us the workflow. You will have a compliance-aware deployment in your environment meeting every acceptance criterion you signed off on.
Learn more about our work in Pharma & Life Sciences and how production AI can meet both speed and governance requirements.
QueryNow leads AI transformation for enterprises in the US and Europe. Founded in Germany in 2014, we build the foundation enterprise AI runs on, and the agents that run on it, for pharma, healthcare, manufacturing and financial services organizations on Azure and AWS.
The Monday digest
The three posts worth your time each week, one paragraph each. From the people building production AI.



